Maximum Daily Dose of Clavulanic Acid
The maximum daily dose of clavulanic acid is 250 mg for adults and 6.4 mg/kg/day for children, regardless of the amoxicillin dose used. 1
Adult Dosing
For adults, the FDA-approved maximum clavulanic acid dose is 250 mg per day, which can be administered as:
- 125 mg twice daily (standard dosing with amoxicillin 500 mg or 875 mg)
- 125 mg three times daily (375 mg total daily) is NOT recommended due to tolerability issues
The high-dose amoxicillin-clavulanate formulation for adults specifically provides 4 g amoxicillin with 250 mg clavulanate per day in two divided doses 2. This translates to two tablets of 2000 mg amoxicillin/125 mg clavulanate taken twice daily 3.
Critical caveat: Two 250 mg/125 mg tablets are NOT equivalent to one 500 mg/125 mg tablet because both contain the same 125 mg of clavulanate. Substitution errors can lead to clavulanate overdosing and increased gastrointestinal side effects 1.
Pediatric Dosing
For children, the maximum clavulanic acid dose is 6.4 mg/kg/day administered in two divided doses 4, 2. This is paired with high-dose amoxicillin at 80-90 mg/kg/day for moderate to severe infections or when resistant pathogens are suspected 3, 4.
The pediatric formulation provides a 14:1 ratio of amoxicillin to clavulanate, which allows for higher amoxicillin dosing while keeping clavulanate at safe, tolerable levels 2.
Why This Limit Exists
Clavulanic acid dose is restricted due to tolerability, not efficacy. The primary dose-limiting adverse effect is diarrhea, which increases with higher clavulanate doses 5, 6, 7. Studies show that 125 mg of clavulanate is adequate to inhibit all β-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis 4, making higher doses unnecessary from a microbiological standpoint.
Recent research suggests even lower clavulanate doses (2.85-3.2 mg/kg/day in children) may reduce diarrhea and diaper dermatitis without compromising clinical efficacy 6, though these formulations are not yet standard practice.
Special Populations
Renal impairment: Patients with severe renal dysfunction (GFR <30 mL/min) should not receive the 875 mg/125 mg formulation. Those with GFR 10-30 mL/min should receive 500 mg/125 mg or 250 mg/125 mg every 12 hours, and those with GFR <10 mL/min should receive dosing every 24 hours 1.
Hemodialysis patients: Administer an additional dose both during and at the end of dialysis 1.